BioLife Solutions (NASDAQ:BLFS) Given New $31.00 Price Target at Northland Securities

BioLife Solutions (NASDAQ:BLFS) had its target price upped by equities research analysts at Northland Securities from $28.00 to $31.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Northland Securities’ price target would indicate a potential upside of 14.35% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. TD Cowen upped their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Benchmark reissued a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Craig Hallum boosted their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. KeyCorp upped their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, HC Wainwright cut their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Stock Down 0.6 %

Shares of BioLife Solutions stock opened at $27.11 on Wednesday. The company has a market cap of $1.26 billion, a P/E ratio of -25.58 and a beta of 1.92. BioLife Solutions has a 1 year low of $14.50 and a 1 year high of $28.88. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock has a 50-day moving average price of $25.83 and a 200 day moving average price of $24.25.

Insider Buying and Selling at BioLife Solutions

In other news, EVP Aby J. Mathew sold 7,604 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the sale, the executive vice president now directly owns 276,315 shares of the company’s stock, valued at approximately $7,551,688.95. This represents a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 64,259 shares of company stock valued at $1,424,708 in the last 90 days. 2.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BioLife Solutions

Several large investors have recently bought and sold shares of BLFS. Stifel Financial Corp grew its stake in shares of BioLife Solutions by 5.4% in the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after purchasing an additional 670 shares during the period. GAMMA Investing LLC raised its position in BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 748 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in BioLife Solutions by 5.8% in the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock worth $296,000 after purchasing an additional 753 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in shares of BioLife Solutions during the third quarter worth $28,000. Finally, Curi RMB Capital LLC increased its stake in shares of BioLife Solutions by 0.5% in the third quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock valued at $10,565,000 after buying an additional 2,283 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.